Effects of Antiplatelet Drugs on Colon Cancer in the Elderly
Effects of Antiplatelet Drugs on Colon Cancer in the Elderly
批准号:
8701850
负责人:
LENARD M LICHTENBERGER
金额:
$21.33万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-04-01 至 2016-03-31
关键词:
AcuteAdhesionsAdverse effectsAffectAgeAge-YearsAnimalsAnti Inflammatory AnalgesicsAntihypertensive AgentsAntiplatelet DrugsApoptosisAspirinAzoxymethaneBiological ModelsBleeding time procedureBlood PlateletsCancer Cell GrowthCancer EtiologyCancer ModelCancer PatientCause of DeathCellsCessation of lifeChemopreventionChemopreventive AgentClinicalClinical ResearchCoagulantsColon CarcinomaColorectalColorectal CancerDegenerative DisorderDipyridamoleDiseaseDistantDoseDrug CostsDrug FormulationsDrug toxicityDrug usageEffectivenessElderlyEndotheliumEpithelialExtravasationFDA approvedFamilyGastrointestinal tract structureGoalsGrantGrowthGrowth FactorHealthcareHemorrhageHumanImmuneIn VitroIncidenceKiller CellsKnowledgeLabelLaboratoriesLecithinLifeMalignant - descriptorMalignant NeoplasmsMesenchymalMeta-AnalysisMetforminModelingMovementMusNeoplasm Circulating CellsNeoplasm MetastasisNon-Steroidal Anti-Inflammatory AgentsOncologistPTGS2 genePatientsPharmaceutical PreparationsPlatelet ActivationPlatelet Count measurementPlatelet aggregationPlatelet-Derived Growth FactorPopulationProcessProliferatingPropranololRecommendationReportingRiskRisk FactorsRisk ReductionRoleSalesSecond Primary CancersSiteSolid NeoplasmSurfaceTestingThrombosisTissuesTransforming Growth FactorsUlcerVascular Endothelial Growth Factorsage effectage relatedagedangiogenesiscancer cellcancer diagnosiscancer initiationcarcinogenesiscardiovascular risk factorcell growthchemotherapeutic agentcirculating cancer cellclopidogrelcolorectal cancer preventiondiabeticdisorder riskgastrointestinalhuman subjectin vivojuvenile animalmortalityneoplastic cellpatient populationpopulation basedpreventpublic health relevanceresponsethrombocytosistreatment strategy
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Malignant cancers are the second leading cause of death in the USA with colorectal cancer being the second most fatal cancer. The elderly population is particularly at risk for colorectal cancer as its incidence increases with age. Circulating platelets are known to change with age which may affect a variety of degenerative diseases including cancers. Platelets are implicated in the promotion of carcinogenesis and its metastatic spread, and their circulating numbers are reported to be elevated in a number of solid tumors including colorectal cancer. Platelet aggregation with circulating cancer cells appears to protect the cancer cells and promote their metastasis. Recent studies of large populations of patients on low dose antiplatelet therapy (low dose aspirin) for cardiovascular risk
reduction, have reported that aspirin confers significant protection against cancer formation, metastases and death. Thus, it is possible that the known chemopreventive activity of aspirin may be related to its antiplatelet action. Our hypothesis is that modulation of platelet activity i important for prevention of colorectal cancer and suppression of metastatic growth. One limitation to the widespread use of aspirin for chemoprevention is its side effect to induce acute gastrointestinal (GI) bleeding that may become life threatening if untreated. This is particularly problem for the elderly, as advanced age is a risk factor for NSAID-induced GI ulceration/bleeding. A recently FDA-approved aspirin product that is GI- safer (Aspirin-PC/PL2200) developed by the PI's laboratory may offer a means to provide significant chemoprevention with reduced GI side effects. We propose to investigate: 1) the in vitro cross-talk between platelets from young and elderly subjects and cancer cells, and their responsiveness to antiplatelet drugs, including various aspirin formulations, notably Aspirin-PC, and other agents; and 2) an in vivo colon cancer [models of both pre-cancer initiation] and metastatic growth in young and old animals for sensitivity to antiplatelet drugs. These studies will contribute to knowledge about the role of platelets in chemoprevention of colorectal cancer in the elderly, and may offer a timely and safe approach to reduce the metastatic spread of cancer in the elderly.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Aspirin-PC for Chemoprevention of Colorectal Cancer
-
批准号:8837775
-
项目类别:
-
资助金额:$14.69万
-
财政年份:2014
-
负责人:LENARD M LICHTENBERGER
-
依托单位:
Effects of Antiplatelet Drugs on Colon Cancer in the Elderly
-
批准号:8829798
-
项目类别:
-
资助金额:$16.63万
-
财政年份:2014
-
负责人:LENARD M LICHTENBERGER
-
依托单位:
Aspirin-PC for Chemoprevention of Colorectal Cancer
-
批准号:9932670
-
项目类别:
-
资助金额:$6.5万
-
财政年份:2013
-
负责人:LENARD M LICHTENBERGER
-
依托单位:
Aspirin-PC for Chemoprevention of Colorectal Cancer
-
批准号:8522788
-
项目类别:
-
资助金额:$14.73万
-
财政年份:2013
-
负责人:LENARD M LICHTENBERGER
-
依托单位:
PC-NSAIDs for Chemoprevention of Colorectal Cancer
-
批准号:8539588
-
项目类别:
-
资助金额:$7.14万
-
财政年份:2012
-
负责人:LENARD M LICHTENBERGER
-
依托单位:
PC-NSAIDs for Chemoprevention of Colorectal Cancer
-
批准号:8401434
-
项目类别:
-
资助金额:$7.6万
-
财政年份:2012
-
负责人:LENARD M LICHTENBERGER
-
依托单位:
Gastrointestinal safety and therapeutics of oil-based Phosphatidylcholine-NSAIDS
-
批准号:8009629
-
项目类别:
-
资助金额:$3.75万
-
财政年份:2010
-
负责人:LENARD M LICHTENBERGER
-
依托单位:
NSAID-Phosphatidylcholine Association: Insight in GI Ulcer Pathogenesis/Therapy
-
批准号:7943076
-
项目类别:
-
资助金额:$49.99万
-
财政年份:2009
-
负责人:LENARD M LICHTENBERGER
-
依托单位:
NSAID-Phosphatidylcholine Association: Insight in GI Ulcer Pathogenesis/Therapy
-
批准号:7817520
-
项目类别:
-
资助金额:$49.31万
-
财政年份:2009
-
负责人:LENARD M LICHTENBERGER
-
依托单位:
GI safety and therapeutics of oil-based PC-NSAIDs
-
批准号:6740074
-
项目类别:
-
资助金额:$37.5万
-
财政年份:2002
-
负责人:LENARD M LICHTENBERGER
-
依托单位:
GI safety and therapeutics of oil-based PC-NSAIDs
-
批准号:6897137
-
项目类别:
-
资助金额:$38.36万
-
财政年份:2002
-
负责人:LENARD M LICHTENBERGER
-
依托单位:
Gastrointestinal safety and therapeutics of oil-based Phosphatidylcholine-NSAIDS
-
批准号:7364146
-
项目类别:
-
资助金额:$50.16万
-
财政年份:2002
-
负责人:LENARD M LICHTENBERGER
-
依托单位:
Gastrointestinal safety and therapeutics of oil-based Phosphatidylcholine-NSAIDS
-
批准号:7220295
-
项目类别:
-
资助金额:$56.67万
-
财政年份:2002
-
负责人:LENARD M LICHTENBERGER
-
依托单位:
GI safety and therapeutics of oil-based PC-NSAIDs
-
批准号:6587060
-
项目类别:
-
资助金额:$9.9万
-
财政年份:2002
-
负责人:LENARD M LICHTENBERGER
-
依托单位:
Gastrointestinal safety and therapeutics of oil-based Phosphatidylcholine-NSAIDS
-
批准号:7559546
-
项目类别:
-
资助金额:$46.47万
-
财政年份:2002
-
负责人:LENARD M LICHTENBERGER
-
依托单位:
Clinical Studies with Phospholipid-Associated NSAIDs
-
批准号:6321142
-
项目类别:
-
资助金额:$7.48万
-
财政年份:2001
-
负责人:LENARD M LICHTENBERGER
-
依托单位:
INTEGRATIVE BIOLOGY
-
批准号:8611915
-
项目类别:
-
资助金额:$15.52万
-
财政年份:2001
-
负责人:LENARD M LICHTENBERGER
-
依托单位:
INTEGRATIVE BIOLOGY
-
批准号:8474134
-
项目类别:
-
资助金额:$16.93万
-
财政年份:2001
-
负责人:LENARD M LICHTENBERGER
-
依托单位:
Clinical Studies with Phospholipid-Associated NSAIDs
-
批准号:6524481
-
项目类别:
-
资助金额:$6.72万
-
财政年份:2001
-
负责人:LENARD M LICHTENBERGER
-
依托单位:
INTEGRATIVE BIOLOGY
-
批准号:9024510
-
项目类别:
-
资助金额:$15.52万
-
财政年份:2001
-
负责人:LENARD M LICHTENBERGER
-
依托单位:
海外基金